Preliminary Results for New Halaven Breast Cancer Indication Announced

Share this content:

(ChemotherapyAdvisor) – Pharmaceutical company Eisai (Tokyo, Japan) announced in a July 10 press release that it has preliminary results of a phase 3 study (Study 301) comparing Halaven® (eribulin mesylate) vs capecitabine in locally advanced or metastatic breast cancer patients in whom prior treatment with both an anthracycline and taxane has failed.

Patients (N=1,102) enrolled in this open-label, randomized, 2-parallel-arm, multicenter study were randomized to receive either Halaven 1.4mg/m2/day (administered intravenously on days 1 and 8, every 21 days) or capecitabine 2.5g/m2/day (administered orally on days 1 to 14, every 21 days) in accordance with their HER2 status.   

“The trial did not meet the pre-specified criteria for either of the co-primary end points of overall survival (OS) and progression-free survival (PFS),” the company wrote. “The study did show, however, a trend toward improved OS for patients who received Halaven compared with capecitabine, but the improvement was not statistically significant. No difference was seen in PFS. Furthermore, data showed that the safety profile of Halaven was consistent with that reported in previous clinical studies.”

According to the press release, the company is currently conducting a detailed analysis of these preliminary data, including the secondary end points and subgroup analyses pre-specified in the study protocol, and will work closely with the health authorities towards potential regulatory filing.

Halaven, a non-taxane, microtubule dynamics inhibitor with a novel mechanism of action, is currently approved for the treatment of breast cancer in 37 countries worldwide, including Japan, the United States, European Union (EU) member states and Singapore.

Press release

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs